Keyword Analysis & Research: mirapex for depression
Keyword Research: People who searched mirapex for depression also searched
Search Results related to mirapex for depression on Search Engine
-
Pramipexole in Depression - Mechanism of Action and Dosing
https://psychscenehub.com/psychinsights/pramipexole-treatment-resistant-depression/
WebFeb 17, 2020 · Pramipexole and potentially other dopamine agonists may be useful in the treatment of refractory depression. Pramipexole currently does not have FDA or TGA approval in the US or Australia for the treatment of depression.
DA: 30 PA: 35 MOZ Rank: 80
-
Clinical Experience With High-Dosage Pramipexole in Patients …
https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2015.15060788
WebFeb 1, 2016 · Dopamine agonists, such as pramipexole—a relatively selective dopamine D 3 receptor agonist—are thus potential treatments for depression, especially anhedonic depression. D 3 receptors are found in the mesolimbic system, which in turn has been implicated in the motoric and hedonic deficits in depression ( 9 , 10 ).
DA: 31 PA: 61 MOZ Rank: 8
-
Pramipexole in the treatment of unipolar and bipolar depression.
https://pubmed.ncbi.nlm.nih.gov/31111467/
WebPMID: 31111467. DOI: 10.1111/acps.13055. Abstract. Objective: Several depressed patients do not respond to traditional antidepressants. Our aim was to systematically review the effectiveness and safety of pramipexole in unipolar and bipolar depression.
DA: 43 PA: 87 MOZ Rank: 77
-
Pramipexole in Treatment Resistant-Depression, Possible Role of
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143506/
WebDec 2, 2016 · However, pramipexole, a relatively selective D3 dopamine agonist has shown to relieve depression in Parkinson's disease. Also, in chronic and severe treatment-resistant depressed patients, including bipolar disorder, pramipexole at high doses has shown promising response ( Fawcett et al, 2016 ).
DA: 10 PA: 17 MOZ Rank: 22
-
Pramipexole in treatment-resistant depression: an extended
https://pubmed.ncbi.nlm.nih.gov/15549689/
WebWe evaluated the long-term antidepressant safety and response of adjunctive pramipexole, a D2-D3 dopamine agonist, in the course of drug-resistant depression. Twenty-three patients with treatment-resistant major depressive episode (MDE) were followed up after a 16-week pramipexole add-on trial.
DA: 75 PA: 60 MOZ Rank: 83
-
Pramipexole for the Treatment of Depression: Efficacy and …
https://link.springer.com/chapter/10.1007/7854_2023_458
WebApr 29, 2020 · Pramipexole’s therapeutic utility in depression is likely to be expressed through alterations in reward mechanisms which are strongly influenced by dopamine pathways and are known to function abnormally in depressed patients.
DA: 57 PA: 61 MOZ Rank: 39
-
Pramipexole for Depression | American Journal of Psychiatry
https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.159.2.320-a
WebFeb 1, 2002 · Initial reports suggested the use of pramipexole as an augmentation for current treatment with antidepressants—later and more hesitantly it was suggested as primary therapy. I am aware of no systematic large-scale studies of pramipexole as a treatment for depression.
DA: 64 PA: 42 MOZ Rank: 82
-
Experimental Therapies for Treatment-Resistant Depression: …
https://ncbi.nlm.nih.gov/pmc/articles/PMC6103647/
WebJul 16, 2018 · Pramipexole, a dopamine receptor D2 and D3 agonist, has been shown to be effective in reducing depression and to result in long-term improvement for patients with TRD (25, 26). Because higher doses might be needed to attain therapeutic response with pramipexole, Fawcett et al. recommended that clinicians start at low dosage, slow …
DA: 14 PA: 78 MOZ Rank: 57
-
Preliminary Evidence of Efficacy and Target Engagement of Pramipexole
https://prcp.psychiatryonline.org/doi/10.1176/appi.prcp.20210042
WebApr 30, 2022 · Pramipexole is a dopamine receptor agonist with high affinity for the D 3 receptor, possibly with additional anti‐inflammatory properties ( 1, 2 ). Pramipexole has beneficial effects on symptoms of depression and anhedonia in patients with Parkinson's disease (PD), partly independent of motor symptom improvement ( 3 ).
DA: 67 PA: 7 MOZ Rank: 20
-
Efficacy and safety of 24-week pramipexole augmentation in …
https://www.sciencedirect.com/science/article/abs/pii/S0278584621001846
WebJan 10, 2022 · Pramipexole is a dopamine agonist with potential antidepressant, neuroprotective, antioxidant and anti-inflammatory activity. In the present study we investigated the 24 weeks effect and safety of traditional AD augmentation with pramipexole for treatment-resistant depression.
DA: 36 PA: 88 MOZ Rank: 58
